Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

09 Mar 20265 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Intrahepatic Cholangiocarcinoma (Icc) · Phase 2 · Enrollment 25 · Sponsor: West China Hospital

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 09 Mar 2026. The item focuses on Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial). Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT06859684

Open Original Source More Feed Items

Related by Condition/Drug

Nat Rev OncRelated by Specialty

Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC

Oncology • 20 May 2026

Br J CancerRelated by Specialty

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

Oncology • 19 May 2026

Nat Rev OncRelated by Specialty

Source

ClinicalTrials.gov

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

GIST

Clinical Editorial

Summary

Source Reference

Related by Condition/Drug

Current evidence and future directions for KIM-1 as a blood-based biomarker in RCC

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons

Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction

Autonomous pathology research using agentic AI shows potential in oncology

SLIRP Maintains Mitochondrial mRNA Stability and OXPHOS in Colorectal Cancer